Genetic Tools and Technologies Related News

VariantFind™ by Ranomics announces distribution agreement with Axil Scientific

TORONTO, CANADA (September 21 2018) – Ranomics, a leading provider of DNA variant libraries and screening technologies through its VariantFindTM technology, today announces a distribution agreement with Axil Scientific to bring VariantFind DNA libraries into Singapore. “Singapore has a strong and [...]

How one company is empowering synthetic biology by making high-fidelity DNA at scale

This article is brought to you by DCVC (Data Collective), a leading deep tech and synthetic biology venture capital firm that backs entrepreneurs solving some the world’s hardest problems computationally -- from industrial biotech to algorithmic drug discovery to smart [...]

Maxygen Appoints Steven B. Riedmuller as Chief Executive Officer

SUNNYVALE, CA Sept , 18th 2018 – Maxygen, a provider of high quality services to clients in synthetic biology, metabolic engineering, gene therapy, immunotherapy, and gene editing through application of its molecular breeding technology, is pleased to announce the appointment [...]

Thermo Fisher Scientific Expands Genome Editing IP Portfolio

New license agreements for CRISPR technology from Broad Institute and ERS Genomics extend industry-leading genome editing capabilities CARLSBAD, Calif., Sept. 18, 2018 /PRNewswire/ -- Thermo Fisher Scientific, Inc., the world leader in serving science, has licensed CRISPR technologies from the [...]

CRISPR Therapeutics and ViaCyte Announce Strategic Collaboration to Develop Gene-Edited Stem Cell-Derived Therapy for Diabetes

- Aims to develop an immune-evasive stem cell therapy as a potentially curative treatment for diabetes - - Parties will collaborate through commercialization and share costs and profits worldwide - ZUG, Switzerland and CAMBRIDGE, Mass. and SAN DIEGO, Sept. 17, [...]

Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

FOSTER CITY, Calif. and DURHAM, NC, Sept 12, 2018 – Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B [...]